iA Global Asset Management Inc. Has $3.44 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

iA Global Asset Management Inc. lowered its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,280 shares of the medical device company's stock after selling 3,818 shares during the period. iA Global Asset Management Inc.'s holdings in DexCom were worth $3,444,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Teacher Retirement System of Texas raised its holdings in shares of DexCom by 269.4% during the 4th quarter. Teacher Retirement System of Texas now owns 28,759 shares of the medical device company's stock valued at $2,237,000 after purchasing an additional 20,974 shares in the last quarter. Royal London Asset Management Ltd. increased its position in DexCom by 4.7% during the fourth quarter. Royal London Asset Management Ltd. now owns 170,949 shares of the medical device company's stock worth $13,295,000 after buying an additional 7,711 shares during the last quarter. Harvest Fund Management Co. Ltd increased its position in DexCom by 42.5% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 26,307 shares of the medical device company's stock worth $2,013,000 after buying an additional 7,848 shares during the last quarter. Vinva Investment Management Ltd bought a new position in DexCom during the fourth quarter valued at about $1,030,000. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its position in shares of DexCom by 107.9% in the fourth quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,855 shares of the medical device company's stock worth $533,000 after buying an additional 3,558 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Remove Ads

DexCom Price Performance

Shares of DexCom stock traded down $1.77 during trading on Tuesday, hitting $73.55. 3,240,371 shares of the company's stock traded hands, compared to its average volume of 3,915,036. The company has a market cap of $28.74 billion, a PE ratio of 51.43, a PEG ratio of 2.30 and a beta of 1.28. The firm's fifty day moving average price is $83.24 and its 200 day moving average price is $77.07. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 over the last three months. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.